Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer

  Free Subscription


15.08.2022

1 Aktuelle Urol
1 Am J Transl Res
1 Anticancer Drugs
1 ANZ J Surg
4 Beijing Da Xue Xue Bao Yi Xue Ban
1 BJUI Compass
1 BMC Gastroenterol
1 BMC Genom Data
1 Br J Hosp Med (Lond)
1 Cancer Control
1 Cancer Med
3 Cancers (Basel)
1 Cells
2 Clin Genitourin Cancer
1 Clin Nucl Med
1 Eur J Cancer Care (Engl)
5 Eur Urol
1 Folia Neuropathol
2 Front Immunol
1 Front Oncol
1 Front Surg
1 Gen Physiol Biophys
2 Hum Pathol
1 Indian J Cancer
1 Int J Environ Res Public Health
2 Int J Mol Sci
1 Int J Nurs Pract
1 Int Urol Nephrol
1 J Clin Oncol
1 J Nanobiotechnology
1 J Natl Compr Canc Netw
1 J Oncol
2 J Urol
1 Jpn J Clin Oncol
1 Lab Invest
1 Molecules
1 Nat Commun
1 Oncol Lett
1 Pathol Res Pract
1 Transl Androl Urol
2 Urol Clin North Am
1 Urol Oncol
4 Urologie


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aktuelle Urol



  1. Aktuelle Urol. 2022;53:314-315.
    PubMed        


    Am J Transl Res

  2. LI R, Chen X, Li X, Huang G, et al
    A four-miRNA signature in serum as a biomarker for bladder cancer diagnosis.
    Am J Transl Res. 2022;14:4606-4616.
    PubMed         Abstract available


    Anticancer Drugs

  3. DIAN X, Kun L, Xin W, SongBai Y, et al
    Successful treatment of advanced muscle-invasive bladder cancer with the combined therapy of toripalimab and chemotherapy: a case report.
    Anticancer Drugs. 2022 Aug 9. pii: 00001813-990000000-00034.
    PubMed         Abstract available


    ANZ J Surg

  4. LAW ZW, Anbudurai M, Lee CSN, Lee LS, et al
    Vulvar urothelial carcinoma recurrence in an intact bladder free of disease.
    ANZ J Surg. 2022;92.
    PubMed        


    Beijing Da Xue Xue Bao Yi Xue Ban

  5. LI ZH, Xu CR, Liu Y, Guan H, et al
    [Correlation between daily fluid intake behavioral habits and pathological characteristics of upper tract urothelial carcinoma].
    Beijing Da Xue Xue Bao Yi Xue Ban. 2022;54:621-627.
    PubMed         Abstract available

  6. YING YC, Tang Q, Yang KW, Mi Y, et al
    [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
    Beijing Da Xue Xue Bao Yi Xue Ban. 2022;54:644-651.
    PubMed         Abstract available

  7. WANG F, Qin CP, DU YQ, Liu SJ, et al
    [Optimal surveillance intensity of cystoscopy in intermediate-risk non-muscle invasive bladder cancer].
    Beijing Da Xue Xue Bao Yi Xue Ban. 2022;54:669-673.
    PubMed         Abstract available

  8. DAI X, Wang F, DU YQ, Song YX, et al
    [Correlation between adipokine and clinicopathological features and prognosis in upper tract urothelial carcinoma].
    Beijing Da Xue Xue Bao Yi Xue Ban. 2022;54:605-614.
    PubMed         Abstract available


    BJUI Compass

  9. RUSSELL B, Spencer-Bowdage S, Rigby J, O'Kelly J, et al
    The experience of UK patients with bladder cancer during the second wave of the COVID-19 pandemic.
    BJUI Compass. 2022;3:324-326.
    PubMed        


    BMC Gastroenterol

  10. CHEN X, Chen X, Yu X, He X, et al
    EUS-guided fine needle aspiration provides an open view for duodenal obstruction caused by urothelial carcinoma: a case report.
    BMC Gastroenterol. 2022;22:376.
    PubMed         Abstract available


    BMC Genom Data

  11. LIU JP, Fang YT, Jiang YF, Lin H, et al
    HYAL3 as a potential novel marker of BLCA patient prognosis.
    BMC Genom Data. 2022;23:63.
    PubMed         Abstract available


    Br J Hosp Med (Lond)

  12. HALD OC, Phan YC, Carter CJ
    Urinary bladder paraganglioma with a family history of neurofibromatosis type 1 treated with partial cystectomy.
    Br J Hosp Med (Lond). 2022;83:1-3.
    PubMed        


    Cancer Control

  13. ZHANG L, Geng Z, Hao B, Geng Q, et al
    Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody.
    Cancer Control. 2022;29:10732748221111296.
    PubMed         Abstract available


    Cancer Med

  14. KOTHER AK, Budenbender B, Grune B, Holbach S, et al
    Different patients, different preferences: A multicenter assessment of patients' personality traits and anxiety in shared decision making.
    Cancer Med. 2022;11:2999-3008.
    PubMed         Abstract available


    Cancers (Basel)

  15. DIAMANT E, Roumiguie M, Ingels A, Parra J, et al
    Effectiveness of Early Radical Cystectomy for High-Risk Non-Muscle Invasive Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed         Abstract available

  16. WANG D, Zhang P, Liu Z, Xing' Y, et al
    NXPH4 Promotes Gemcitabine Resistance in Bladder Cancer by Enhancing Reactive Oxygen Species and Glycolysis Activation through Modulating NDUFA4L2.
    Cancers (Basel). 2022;14.
    PubMed         Abstract available

  17. GU L, Chen Y, Li X, Mei Y, et al
    Integrated Analysis and Identification of Critical RNA-Binding Proteins in Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed         Abstract available


    Cells

  18. LAZEBNIK T
    Cell-Level Spatio-Temporal Model for a Bacillus Calmette-Guerin-Based Immunotherapy Treatment Protocol of Superficial Bladder Cancer.
    Cells. 2022;11.
    PubMed         Abstract available


    Clin Genitourin Cancer

  19. ANDERSON CB, Chen L, Chang SS, McKiernan JM, et al
    Intravesical Therapy Compared to Radical Cystectomy Among Patients With Non-Muscle Invasive Bladder Cancer Requiring Additional Treatment After Induction BCG.
    Clin Genitourin Cancer. 2022 Jul 11. pii: S1558-7673(22)00153.
    PubMed         Abstract available

  20. SOLTANZADEH S, Saeedian A, Ghalehtaki R, Ayati M, et al
    Assessment of Tolerability, Response and Complications of Concurrent Chemoradiation With Capecitabine and Cisplatin in Muscle-Invasive Bladder Cancer; A Single Arm Study.
    Clin Genitourin Cancer. 2022 Jul 19. pii: S1558-7673(22)00159.
    PubMed         Abstract available


    Clin Nucl Med

  21. BEYHAN E, Baykal Koca S, Yucetas U, Cermik TF, et al
    18F-FDG PET/CT in Urethral Metastases From Bladder Cancer.
    Clin Nucl Med. 2022 Aug 4. pii: 00003072-990000000-00227.
    PubMed         Abstract available


    Eur J Cancer Care (Engl)

  22. HAJJAR M, Rezazadeh A, Naja F, Kardoust Parizi M, et al
    Association of Dietary Approaches to Stop Hypertension diet and risk of bladder cancer: A case-control study.
    Eur J Cancer Care (Engl). 2022 Aug 10:e13664. doi: 10.1111/ecc.13664.
    PubMed         Abstract available


    Eur Urol

  23. CARVALHO FLF, Mossanen M, Van Allen EM, Mouw KW, et al
    Reply to Yuxuan Song, Yiqing Du, and Tao Xu's Letter to the Editor re: Matthew Mossanen, Filipe L.F. Carvalho, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73.
    Eur Urol. 2022 Aug 6. pii: S0302-2838(22)02534.
    PubMed        

  24. CATTO JWF, Khetrapal P, Ambler G, Williams NR, et al
    Reply to Andreas Skolarikos's Words of Wisdom re: Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Randomized Clinical
    Eur Urol. 2022 Aug 6. pii: S0302-2838(22)02535.
    PubMed        

  25. SONG Y, Du Y, Xu T
    Re: Matthew Mossanena, Filipe L.F. Carvalhoa, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73.
    Eur Urol. 2022 Aug 5. pii: S0302-2838(22)02530.
    PubMed        

  26. SKOLARIKOS A
    Re: Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Randomized Clinical Trial.
    Eur Urol. 2022 Aug 3. pii: S0302-2838(22)02525.
    PubMed        

  27. DE RUITER BM, van Hattum JW, Lipman D, de Reijke TM, et al
    Phase 1 Study of Chemoradiotherapy Combined with Nivolumab +/- Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer.
    Eur Urol. 2022 Aug 3. pii: S0302-2838(22)02522.
    PubMed         Abstract available


    Folia Neuropathol

  28. MEHBOOB R, Kurdi M, Baeesa S, Fawzy Halawa T, et al
    Immunolocalization of neurokinin 1 receptor in WHO grade 4 astrocytomas, oral squamous cell and urothelial carcinoma.
    Folia Neuropathol. 2022;60:165-176.
    PubMed         Abstract available


    Front Immunol

  29. XU T, Xu W, Zheng Y, Li X, et al
    Comprehensive FGFR3 alteration-related transcriptomic characterization is involved in immune infiltration and correlated with prognosis and immunotherapy response of bladder cancer.
    Front Immunol. 2022;13:931906.
    PubMed         Abstract available

  30. ZHANG Z, Yu Y, Li P, Wang M, et al
    Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer.
    Front Immunol. 2022;13:954616.
    PubMed         Abstract available


    Front Oncol

  31. ROVIELLO G, Catalano M, Santi R, Santoni M, et al
    Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments.
    Front Oncol. 2022;12:912699.
    PubMed         Abstract available


    Front Surg

  32. WARD K, Kitchen MO, Mathias SJ, Khanim FL, et al
    Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning.
    Front Surg. 2022;9:912438.
    PubMed         Abstract available


    Gen Physiol Biophys

  33. PARK C, Cha HJ, Lee H, Jeong JW, et al
    Induction of apoptosis through inactivation of ROS-dependent PI3K/Akt signaling pathway by platycodin D in human bladder urothelial carcinoma cells.
    Gen Physiol Biophys. 2022;41:263-274.
    PubMed         Abstract available


    Hum Pathol

  34. EVARISTO G, Khadang B, Kool R, Marcq G, et al
    Morphologic alterations post trimodal therapy in muscle-invasive urothelial carcinoma: understanding the impact of post-treatment changes on the pathological interpretation and their potential clinical correlates.
    Hum Pathol. 2022;126:2-8.
    PubMed         Abstract available

  35. REISWICH V, Akdeniz G, Lennartz M, Menz A, et al
    Large-scale human tissue analysis identifies Uroplakin 1b as a putative diagnostic marker in surgical pathology.
    Hum Pathol. 2022;126:108-120.
    PubMed         Abstract available


    Indian J Cancer

  36. MOHAMEDALI R, Adhya AK, Mandal S, Mitra S, et al
    Expression of mismatch repair proteins in urothelial carcinoma of the urinary bladder.
    Indian J Cancer. 2022;59:279-281.
    PubMed         Abstract available


    Int J Environ Res Public Health

  37. MALINARIC R, Mantica G, Lo Monaco L, Mariano F, et al
    The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers-What Should a Urologist Really Know?
    Int J Environ Res Public Health. 2022;19.
    PubMed         Abstract available


    Int J Mol Sci

  38. MATUSZCZAK M, Kiljanczyk A, Salagierski M
    A Liquid Biopsy in Bladder Cancer-The Current Landscape in Urinary Biomarkers.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available

  39. SILINA L, Dufour F, Rapinat A, Reyes C, et al
    Tyro3 Targeting as a Radiosensitizing Strategy in Bladder Cancer through Cell Cycle Dysregulation.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available


    Int J Nurs Pract

  40. DONEGAN B, Kingston L
    Quality of life following formation of an ileal conduit due to urinary bladder neoplasm: A systematic review.
    Int J Nurs Pract. 2022;28:e12988.
    PubMed         Abstract available


    Int Urol Nephrol

  41. REIS LO, Salustiano ACC, Capibaribe DM, Kiehl IGA, et al
    Castration immunoregulates toll-like receptor-4 in male bladder cancer.
    Int Urol Nephrol. 2022 Aug 8. pii: 10.1007/s11255-022-03336.
    PubMed         Abstract available


    J Clin Oncol

  42. ZHANG S
    Neoadjuvant Programmed Cell Death Protein 1 and Chemotherapy in Combination in Muscle-Invasive Urothelial Cancer: Promising, But Not Deserving to Try Further.
    J Clin Oncol. 2022;40:2656.
    PubMed         Abstract available


    J Nanobiotechnology

  43. CHIN YC, Yang LX, Hsu FT, Hsu CW, et al
    Iron oxide@chlorophyll clustered nanoparticles eliminate bladder cancer by photodynamic immunotherapy-initiated ferroptosis and immunostimulation.
    J Nanobiotechnology. 2022;20:373.
    PubMed         Abstract available


    J Natl Compr Canc Netw

  44. FLAIG TW, Spiess PE, Abern M, Agarwal N, et al
    NCCN Guidelines(R) Insights: Bladder Cancer, Version 2.2022.
    J Natl Compr Canc Netw. 2022;20:866-878.
    PubMed         Abstract available


    J Oncol

  45. CAI W, Wei M, Su Z
    MITF-Mediated lncRNA CCDC183-As1 Promotes the Tumorigenic Properties and Aerobic Glycolysis of Bladder Cancer via Upregulating TCF7L2.
    J Oncol. 2022;2022:6785956.
    PubMed         Abstract available


    J Urol

  46. TERRITO A, Gallioli A, Diana P, Boissier R, et al
    DNA Methylation Urine Biomarkers Test in the Diagnosis of Upper Tract Urothelial Carcinoma: Results from a Single-Center Prospective Clinical Trial.
    J Urol. 2022;208:570-579.
    PubMed         Abstract available

  47. MEEKS JJ, Sexton WJ, Clark PE
    Sequential Chemotherapy with Gemcitabine and Docetaxel: Breaking the Chains of bacillus Calmette-Guerin.
    J Urol. 2022;208:526-527.
    PubMed        


    Jpn J Clin Oncol

  48. HUANG Y, Wei L, Huang Y, Wen S, et al
    Identification of distinct genomic features reveals frequent somatic AHNAK and PTEN mutations predominantly in primary malignant melanoma presenting in the ureter.
    Jpn J Clin Oncol. 2022;52:922-935.
    PubMed         Abstract available


    Lab Invest

  49. WANG L, Wu S, He H, Ai K, et al
    CircRNA-ST6GALNAC6 increases the sensitivity of bladder cancer cells to erastin-induced ferroptosis by regulating the HSPB1/P38 axis.
    Lab Invest. 2022 Aug 9. pii: 10.1038/s41374-022-00826.
    PubMed         Abstract available


    Molecules

  50. LIGOR T, Adamczyk P, Kowalkowski T, Ratiu IA, et al
    Analysis of VOCs in Urine Samples Directed towards of Bladder Cancer Detection.
    Molecules. 2022;27.
    PubMed         Abstract available


    Nat Commun

  51. XIAO K, Zhang N, Li F, Hou D, et al
    Pro-oxidant response and accelerated ferroptosis caused by synergetic Au(I) release in hypercarbon-centered gold(I) cluster prodrugs.
    Nat Commun. 2022;13:4669.
    PubMed         Abstract available


    Oncol Lett

  52. WANG Y, Shao W, Feng Y, Tang J, et al
    Prognostic value and potential biological functions of ferroptosis-related gene signature in bladder cancer.
    Oncol Lett. 2022;24:301.
    PubMed         Abstract available


    Pathol Res Pract

  53. HAN Z, Tian Y, Liu Q, Zhao Y, et al
    LncRNA PTAR activates the progression of bladder cancer by modulating miR-299-3p/CD164 axis.
    Pathol Res Pract. 2022;237:153994.
    PubMed         Abstract available


    Transl Androl Urol

  54. JIN K, He M, Chen B, Zhou X, et al
    A single-sample mRNA molecular classification of bladder cancer predicting prognosis and response to immunotherapy.
    Transl Androl Urol. 2022;11:943-958.
    PubMed         Abstract available


    Urol Clin North Am

  55. XU AJ, Mishra K, Lee YS, Zhao LC, et al
    Robotic-Assisted Lower Genitourinary Tract Reconstruction.
    Urol Clin North Am. 2022;49:507-518.
    PubMed         Abstract available

  56. HEBERT KJ, Matta R, Myers JB
    Patient Selection and Outcomes of Urinary Diversion.
    Urol Clin North Am. 2022;49:533-551.
    PubMed         Abstract available


    Urol Oncol

  57. SCHERNUK J, Gonzalez MI, Vecchio F, Alfieri AG, et al
    Clinical and histopathological features of bladder cancer following radiotherapy for prostate cancer: A comparative study.
    Urol Oncol. 2022 Aug 6. pii: S1078-1439(22)00240.
    PubMed         Abstract available


    Urologie

  58. OSWALD D, Pallauf P, Deininger S, Herrmann TRW, et al
    [Safety and efficacy of en bloc vs. conventional transurethral resection of bladder tumors: a meta-analysis and systematic review].
    Urologie. 2022;61:644-652.
    PubMed         Abstract available

  59. BURGER R, Jarczyk J, Westhoff N, Worst TS, et al
    [Immunotherapy in urologic oncology : Response and treatment interruptions due to adverse events in a bicentric real-world analysis].
    Urologie. 2022;61:759-766.
    PubMed         Abstract available

  60. ECKSTEIN M
    [Immunological biomarker research in uro-oncology-using the example of urothelial cancer].
    Urologie. 2022;61:734-738.
    PubMed         Abstract available

  61. MELZER MK, Zehe V, Zengerling F, Wezel F, et al
    [Organoids as a milestone on the way to personalized treatment of urothelial carcinoma: a systematic review].
    Urologie. 2022;61:745-752.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: